thalidomide has been researched along with Autoimmune Disease in 29 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide, an agent with antiangiogenic and immunomodulatory properties, is therapeutically effective in multiple myeloma, leprosy, and autoimmune diseases." | 7.72 | Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. ( Fruehauf, S; Goldschmidt, H; Hartschuh, W; Ho, AD; Moehler, T; Neben, K; Witzens, M, 2004) |
| "Pemphigus vegetans is a rare variant of pemphigus vulgaris." | 5.62 | Post-cesarean section pemphigus vegetans in a young woman treated with methylprednisolone and thalidomide. ( Jiang, L; Li, W; Qiu, X; Yuan, P, 2021) |
| " Although corticosteroids are usually the first-line therapy for non-infectious uveitis, their long-term use is limited by potentially serious side effects in all possible delivery routes." | 5.56 | Intravitreal thalidomide ameliorates inflammation in a model of experimental uveitis induced by BCG. ( Castro, BFM; Cenachi, SPF; Cotta, OAL; Fialho, SL; Guerra, MCA; Paiva, MRB; Silva, LM; Silva-Cunha, A; Vasconcelos-Santos, DV; Vieira, LC, 2020) |
| "Thalidomide has shown anti-inflammatory or immunosuppressive actions in several animal models." | 5.27 | Thalidomide for autoimmune disease. ( Hendler, SS; McCarty, MF, 1983) |
| "Thalidomide, an agent with antiangiogenic and immunomodulatory properties, is therapeutically effective in multiple myeloma, leprosy, and autoimmune diseases." | 3.72 | Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. ( Fruehauf, S; Goldschmidt, H; Hartschuh, W; Ho, AD; Moehler, T; Neben, K; Witzens, M, 2004) |
| "Thalidomide has anti-inflammatory properties and shows promise for treating a variety of infectious and autoimmune diseases, but it must be used with strict precautions." | 3.70 | Thalidomide's tightly controlled "comeback". ( Calabrese, LH, 1999) |
| "Although thalidomide has been used with success in the treatment of increasing numbers of autoimmune diseases, the therapeutic effects have not been satisfactorily explained so far." | 3.69 | Immunostimulatory effect of thalidomide in normal C57BL/6 mice is compatible with stimulation of a highly connected central immune system. ( Arala-Chaves, M; Pinto, J; Ribeiro, A; Vilanova, M, 1994) |
| "Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome are rare, severe cutaneous adverse reactions usually triggered by medications." | 2.82 | Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. ( Beecker, J; Jacobsen, A; Langley, A; Mutter, E; Olabi, B; Pardo Pardo, J; Parker, R; Ramsay, T; Saavedra, A; Shelley, A; Stewart, F; Worley, B, 2022) |
| "Thalidomide has immunomodulatory and anti-tumor necrosis factor-α effects as well as antiangiogenic properties, making it useful for a broad spectrum of inflammatory disorders." | 2.52 | Review of thalidomide use in the pediatric population. ( Antaya, RJ; Kim, C; Yang, CS, 2015) |
| "Pemphigus vegetans is a rare variant of pemphigus vulgaris." | 1.62 | Post-cesarean section pemphigus vegetans in a young woman treated with methylprednisolone and thalidomide. ( Jiang, L; Li, W; Qiu, X; Yuan, P, 2021) |
| " Although corticosteroids are usually the first-line therapy for non-infectious uveitis, their long-term use is limited by potentially serious side effects in all possible delivery routes." | 1.56 | Intravitreal thalidomide ameliorates inflammation in a model of experimental uveitis induced by BCG. ( Castro, BFM; Cenachi, SPF; Cotta, OAL; Fialho, SL; Guerra, MCA; Paiva, MRB; Silva, LM; Silva-Cunha, A; Vasconcelos-Santos, DV; Vieira, LC, 2020) |
| "Autoimmune diseases are prevalent among MDS patients." | 1.43 | Autoimmune diseases and myelodysplastic syndromes. ( Al Ali, NH; Bart-Smith, E; Craig, BM; Epling-Burnette, PK; Komrokji, RS; Kordasti, S; Kulasekararaj, A; Lancet, JE; List, AF; Mufti, GJ; Padron, E; Pinilla-Ibarz, J; Zhang, L, 2016) |
| "She was also diagnosed as having a myelofibrosis with myeloid metaplasia (MMM)." | 1.33 | Endolymphatic hydrops as a cause of audio-vestibular manifestations in relapsing polychondritis. ( Horii, A; Kubo, T; Mitani, K; Mizuki, M; Murata, J; Tamura, M, 2006) |
| "Thalidomide has shown anti-inflammatory or immunosuppressive actions in several animal models." | 1.27 | Thalidomide for autoimmune disease. ( Hendler, SS; McCarty, MF, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (10.34) | 18.7374 |
| 1990's | 4 (13.79) | 18.2507 |
| 2000's | 5 (17.24) | 29.6817 |
| 2010's | 12 (41.38) | 24.3611 |
| 2020's | 5 (17.24) | 2.80 |
| Authors | Studies |
|---|---|
| Jacobsen, A | 1 |
| Olabi, B | 1 |
| Langley, A | 1 |
| Beecker, J | 1 |
| Mutter, E | 1 |
| Shelley, A | 1 |
| Worley, B | 1 |
| Ramsay, T | 1 |
| Saavedra, A | 1 |
| Parker, R | 1 |
| Stewart, F | 1 |
| Pardo Pardo, J | 1 |
| da Silva, CO | 1 |
| Dias, AA | 1 |
| da Costa Nery, JA | 1 |
| de Miranda Machado, A | 1 |
| Ferreira, H | 1 |
| Rodrigues, TF | 1 |
| Sousa Santos, JP | 1 |
| Nadaes, NR | 1 |
| Sarno, EN | 1 |
| Saraiva, EM | 1 |
| Schmitz, V | 1 |
| Pessolani, MCV | 1 |
| Castro, BFM | 1 |
| Vieira, LC | 1 |
| Vasconcelos-Santos, DV | 1 |
| Cenachi, SPF | 1 |
| Cotta, OAL | 1 |
| Guerra, MCA | 1 |
| Paiva, MRB | 1 |
| Silva, LM | 1 |
| Silva-Cunha, A | 1 |
| Fialho, SL | 1 |
| Soriano, A | 1 |
| Soriano, M | 1 |
| Espinosa, G | 1 |
| Manna, R | 1 |
| Emmi, G | 1 |
| Cantarini, L | 1 |
| Hernández-Rodríguez, J | 1 |
| Chen, Y | 1 |
| Li, Z | 1 |
| Li, H | 1 |
| Su, W | 1 |
| Xie, Y | 1 |
| Pan, Y | 1 |
| Chen, X | 1 |
| Liang, D | 1 |
| Qiu, X | 1 |
| Yuan, P | 1 |
| Li, W | 1 |
| Jiang, L | 1 |
| Sakkas, LI | 1 |
| Mavropoulos, A | 1 |
| Bogdanos, DP | 1 |
| Gremain, V | 1 |
| Litrowski, N | 1 |
| Boulard, C | 1 |
| Marguet, F | 1 |
| Courville, P | 1 |
| Zarnitsky, C | 1 |
| Langlois, V | 1 |
| Kumar, N | 1 |
| Goldminz, AM | 1 |
| Kim, N | 1 |
| Gottlieb, AB | 1 |
| Gertz, MA | 1 |
| Buadi, FK | 1 |
| Montefusco, V | 2 |
| Galli, M | 1 |
| Spina, F | 1 |
| Stefanoni, P | 1 |
| Mussetti, A | 1 |
| Perrone, G | 1 |
| De Philippis, C | 1 |
| Dalto, S | 1 |
| Maura, F | 1 |
| Bonini, C | 1 |
| Rezzonico, F | 1 |
| Pennisi, M | 1 |
| Roncari, L | 1 |
| Soldarini, M | 1 |
| Dodero, A | 1 |
| Farina, L | 1 |
| Cocito, F | 1 |
| Caprioli, C | 1 |
| Corradini, P | 1 |
| Kiesewetter, B | 1 |
| Raderer, M | 1 |
| Yang, CS | 1 |
| Kim, C | 1 |
| Antaya, RJ | 1 |
| Mann, DL | 1 |
| Komrokji, RS | 1 |
| Kulasekararaj, A | 1 |
| Al Ali, NH | 1 |
| Kordasti, S | 1 |
| Bart-Smith, E | 1 |
| Craig, BM | 1 |
| Padron, E | 1 |
| Zhang, L | 1 |
| Lancet, JE | 1 |
| Pinilla-Ibarz, J | 1 |
| List, AF | 1 |
| Mufti, GJ | 1 |
| Epling-Burnette, PK | 1 |
| Millrine, D | 1 |
| Kishimoto, T | 1 |
| Baidas, S | 1 |
| Tfayli, A | 1 |
| Bhargava, P | 1 |
| Witzens, M | 1 |
| Moehler, T | 1 |
| Neben, K | 1 |
| Fruehauf, S | 1 |
| Hartschuh, W | 1 |
| Ho, AD | 1 |
| Goldschmidt, H | 1 |
| Murata, J | 1 |
| Horii, A | 1 |
| Tamura, M | 1 |
| Mitani, K | 1 |
| Mizuki, M | 1 |
| Kubo, T | 1 |
| Hendler, SS | 1 |
| McCarty, MF | 1 |
| Arala-Chaves, M | 2 |
| Vilanova, M | 2 |
| Ribeiro, A | 2 |
| Pinto, J | 1 |
| Carneiro, J | 1 |
| Calabrese, LH | 1 |
| Saano, V | 1 |
| Neiger, BL | 1 |
| Tuinmann, G | 1 |
| Hegewisch-Becker, S | 1 |
| Hossfeld, DK | 1 |
| Günzler, V | 1 |
| Crain, E | 1 |
| McIntosh, KR | 1 |
| Gordon, G | 1 |
| Pestronk, A | 1 |
| Drachman, DB | 1 |
10 reviews available for thalidomide and Autoimmune Disease
| Article | Year |
|---|---|
Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.
Topics: Acetylcysteine; Adrenal Cortex Hormones; Adult; Autoimmune Diseases; Child; Cyclosporine; Etanercept | 2022 |
Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide.
Topics: Animals; Autoimmune Diseases; Biological Therapy; Colchicine; Dapsone; Evidence-Based Medicine; Feve | 2020 |
Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.
Topics: Aminopyridines; Autoimmune Diseases; Benzamides; Boron Compounds; Cyclopropanes; Eye Diseases; Human | 2017 |
Phosphodiesterase 4-targeted treatments for autoimmune diseases.
Topics: Autoimmune Diseases; Chronic Disease; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III | 2013 |
Review of thalidomide use in the pediatric population.
Topics: Abnormalities, Drug-Induced; Adolescent; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Au | 2015 |
Innate immunity and the failing heart: the cytokine hypothesis revisited.
Topics: Adaptive Immunity; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Autoantibodies; Autoim | 2015 |
A Brighter Side to Thalidomide: Its Potential Use in Immunological Disorders.
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Humans; Leprosy; Models, Molecular; Thalidom | 2017 |
Thalidomide: an old drug with new clinical applications.
Topics: Autoimmune Diseases; HIV Infections; Humans; Immunosuppressive Agents; Neoplasms; Skin Diseases; Tha | 2002 |
[New therapeutic application of thalidomide].
Topics: Autoimmune Diseases; Colitis, Ulcerative; Erythema Multiforme; Female; Histiocytosis; Humans; Immuno | 1996 |
[New indications for thalidomide?].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiogenesis Inhibitors; Animals; Anti-HIV Agents; A | 2001 |
19 other studies available for thalidomide and Autoimmune Disease
| Article | Year |
|---|---|
Neutrophil extracellular traps contribute to the pathogenesis of leprosy type 2 reactions.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Extracellular Traps; Female; Humans; Immunity, | 2019 |
Intravitreal thalidomide ameliorates inflammation in a model of experimental uveitis induced by BCG.
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Humans; Intravitreal Injections; Models, Ani | 2020 |
Apremilast Regulates the Teff/Treg Balance to Ameliorate Uveitis
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; CD4-Positive T-Lymphocytes; Disease Models, | 2020 |
Post-cesarean section pemphigus vegetans in a young woman treated with methylprednisolone and thalidomide.
Topics: Autoimmune Diseases; Cesarean Section; Female; Humans; Methylprednisolone; Pemphigus; Pregnancy; Tha | 2021 |
Necrotizing autoimmune myopathy associated with POEMS syndrome report.
Topics: Autoimmune Diseases; Dexamethasone; Electromyography; Humans; Lenalidomide; Male; Middle Aged; Muscu | 2018 |
Potential new risks of lenalidomide.
Topics: Autoimmune Diseases; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2014 |
Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Hematopoietic Stem Cell Transplantation; Humans | 2014 |
Underlying autoimmune diseases are not aggravated during treatment with lenalidomide in patients with mucosa-associated lymphoid tissue lymphoma: author's reply.
Topics: Autoimmune Diseases; Humans; Immunologic Factors; Male; Multiple Myeloma; Thalidomide | 2015 |
Underlying autoimmune diseases are not aggravated during treatment with lenalidomide in patients with mucosa-associated lymphoid tissue lymphoma.
Topics: Autoimmune Diseases; Humans; Immunologic Factors; Male; Multiple Myeloma; Thalidomide | 2015 |
Autoimmune diseases and myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Azacitidine; Comorbidity; Disease Progression; | 2016 |
Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Aut | 2004 |
Endolymphatic hydrops as a cause of audio-vestibular manifestations in relapsing polychondritis.
Topics: Acute Disease; Audiometry, Evoked Response; Autoimmune Diseases; C-Reactive Protein; Diagnosis, Diff | 2006 |
Thalidomide for autoimmune disease.
Topics: Animal Diseases; Animals; Autoimmune Diseases; Disease Models, Animal; Female; Graft Rejection; Guin | 1983 |
Immunostimulatory effect of thalidomide in normal C57BL/6 mice is compatible with stimulation of a highly connected central immune system.
Topics: Animals; Antibody Formation; Antigens, CD; Autoimmune Diseases; B-Lymphocytes; CD5 Antigens; Flow Cy | 1994 |
The effects of thalidomide treatment on autoimmune-prone NZB and MRL mice are consistent with stimulation of the central immune system.
Topics: Animals; Antigens, CD; Autoimmune Diseases; B-Lymphocytes; CD5 Antigens; Flow Cytometry; Hemolytic P | 1994 |
Thalidomide's tightly controlled "comeback".
Topics: Autoimmune Diseases; HIV Infections; Humans; Immunosuppressive Agents; Leprostatic Agents; Thalidomi | 1999 |
The re-emergence of thalidomide: results of a scientific conference.
Topics: Abnormalities, Drug-Induced; Adjuvants, Immunologic; Adolescent; Adult; Anti-HIV Agents; Anti-Inflam | 2000 |
Thalidomide--a therapy for the immunological consequences of HIV infection?
Topics: Adjuvants, Immunologic; Autoimmune Diseases; B-Lymphocytes; HIV Infections; Humans; Lymphocyte Activ | 1989 |
The effect of thalidomide on experimental autoimmune myasthenia gravis.
Topics: Animals; Antibody Formation; Autoantibodies; Autoimmune Diseases; Drug Evaluation, Preclinical; Immu | 1989 |